Zeen Health is a technology company.
Zeen Health has raised $6.0M across 1 funding round.
Zeen Health has raised $6.0M in total across 1 funding round.
Zeen Health has raised $6.0M in total across 1 funding round.
Zeen Health's investors include Qiming Venture Partners.
Zeen Health is a Shenzhen, China-based healthtech company developing prescription digital therapeutics (PDT) for mental health disorders, with a vision to build the world's leading medical-grade mental health digital therapy platform.[1][2] It offers products like resleep for insomnia therapy and Dayshine for emotion management, using evidence-based cognitive behavioral therapy (CBT) techniques to deliver accessible, clinically validated interventions.[1][4] A randomized control trial (RCT) by Peking University First Hospital demonstrated resleep's significant improvement in sleep quality, and the company is pursuing NMPA approval while expanding pipelines for depression (PDT-002), breast cancer psychological support (SDT-002), and atopic dermatitis (SDT-003).[1] Backed by investors like F-Prime Capital since 2021, Zeen targets underserved mental health needs in China and beyond through AI-enhanced digital solutions.[2][7]
Founded in Shenzhen, China, Zeen Health emerged to address gaps in mental health treatment via digital therapeutics, leveraging CBT and AI for scalable, evidence-based care.[2][4][7] While specific founder details are not detailed in available sources, the company gained early validation through clinical partnerships, including the Peking University RCT for resleep, which proved efficacy and supported regulatory pursuits.[1] Initial investment from F-Prime Capital in 2021 marked a pivotal moment, fueling product development and pipeline expansion amid rising demand for non-pharmacological mental health tools in China.[2]
Zeen Health rides the global surge in digital therapeutics (DTx) and mental health tech, where demand for non-drug alternatives has exploded post-pandemic, especially in China with its vast population and regulatory push via NMPA for PDTs.[1][2] Timing aligns with AI advancements enabling personalized CBT at scale, addressing shortages in mental health professionals amid rising insomnia, depression, and chronic illness burdens.[4][7] Market forces like aging populations, cancer/dermatology comorbidities, and healthtech investments (e.g., F-Prime's 2021 entry) favor Zeen, influencing China's DTx ecosystem by pioneering medical-grade standards and clinical validation.[1][2]
Zeen Health is poised for growth through NMPA approvals, pipeline launches, and international expansion, capitalizing on AI-driven DTx trends and China's mental health crisis. Regulatory wins and further RCTs could accelerate adoption in hospitals and clinics, while partnerships amplify its platform's reach. As DTx matures, Zeen may shape global standards for AI-CBT integration, evolving from China-focused innovator to worldwide mental health leader—building on its evidence-backed foundation to transform accessible therapy.
Zeen Health has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $6.0M Seed | Qiming Venture Partners |